Literature DB >> 35798974

The role of apparent diffusion coefficient histogram metrics for differentiating pediatric medulloblastoma histological variants and molecular groups.

Fabrício Guimarães Gonçalves1, Luis Octavio Tierradentro-Garcia2, Jorge Du Ub Kim2, Alireza Zandifar2, Adarsh Ghosh2, Angela N Viaene3, Dmitry Khrichenko2, Savvas Andronikou2,4, Arastoo Vossough2,4.   

Abstract

BACKGROUND: Medulloblastoma, a high-grade embryonal tumor, is the most common primary brain malignancy in the pediatric population. Molecular medulloblastoma groups have documented clinically and biologically relevant characteristics. Several authors have attempted to differentiate medulloblastoma molecular groups and histology variants using diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps. However, literature on the use of ADC histogram analysis in medulloblastomas is still scarce.
OBJECTIVE: This study presents data from a sizable group of pediatric patients with medulloblastoma from a single institution to determine the performance of ADC histogram metrics for differentiating medulloblastoma variants and groups based on both histological and molecular features.
MATERIALS AND METHODS: In this retrospective study, we evaluated the distribution of absolute and normalized ADC values of medulloblastomas. Tumors were manually segmented and diffusivity metrics calculated on a pixel-by-pixel basis. We calculated a variety of first-order histogram metrics from the ADC maps, including entropy, minimum, 10th percentile, 90th percentile, maximum, mean, median, skewness and kurtosis, to differentiate molecular and histological variants. ADC values of the tumors were also normalized to the bilateral cerebellar cortex and thalami. We used the Kruskal-Wallis and Mann-Whitney U tests to evaluate differences between the groups. We carried out receiver operating characteristic (ROC) curve analysis to evaluate the areas under the curves and to determine the cut-off values for differentiating tumor groups.
RESULTS: We found 65 children with confirmed histopathological diagnosis of medulloblastoma. Mean age was 8.3 ± 5.8 years, and 60% (n = 39) were male. One child was excluded because histopathological variant could not be determined. In terms of medulloblastoma variants, tumors were classified as classic (n = 47), desmoplastic/nodular (n = 9), large/cell anaplastic (n = 6) or as having extensive nodularity (n = 2). Seven other children were excluded from the study because of incomplete imaging or equivocal molecular diagnosis. Regarding medulloblastoma molecular groups, there were: wingless (WNT) group (n = 7), sonic hedgehog (SHH) group (n = 14) and non-WNT/non-SHH (n = 36). Our results showed significant differences among the molecular groups in terms of the median (P = 0.002), mean (P = 0.003) and 90th percentile (P = 0.002) ADC histogram metrics. No significant differences among the various medulloblastoma histological variants were found.
CONCLUSION: ADC histogram analysis can be implemented as a complementary tool in the preoperative evaluation of medulloblastoma in children. This technique can provide valuable information for differentiating among medulloblastoma molecular groups. ADC histogram metrics can help predict medulloblastoma molecular classification preoperatively.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Apparent coefficient diffusion map; Brain; Children; Diffusion-weighted imaging; Histogram; Magnetic resonance imaging; Medulloblastoma; Tumors

Year:  2022        PMID: 35798974     DOI: 10.1007/s00247-022-05411-w

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  45 in total

1.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

2.  3 Tesla MR Study of Cerebellar Medulloblastoma.

Authors:  S Battaglia; L Albini Riccioli; M Zucchelli; M Leonardi
Journal:  Neuroradiol J       Date:  2007-01-14

3.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.

Authors:  Margaret C Thompson; Christine Fuller; Twala L Hogg; James Dalton; David Finkelstein; Ching C Lau; Murali Chintagumpala; Adekunle Adesina; David M Ashley; Stewart J Kellie; Michael D Taylor; Tom Curran; Amar Gajjar; Richard J Gilbertson
Journal:  J Clin Oncol       Date:  2006-03-27       Impact factor: 44.544

Review 4.  Aggressive infantile embryonal tumors.

Authors:  Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 5.  Medulloblastoma in childhood: new biological advances.

Authors:  John R Crawford; Tobey J MacDonald; Roger J Packer
Journal:  Lancet Neurol       Date:  2007-12       Impact factor: 44.182

6.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes.

Authors:  Paul A Northcott; David J H Shih; John Peacock; Livia Garzia; A Sorana Morrissy; Thomas Zichner; Adrian M Stütz; Andrey Korshunov; Jüri Reimand; Steven E Schumacher; Rameen Beroukhim; David W Ellison; Christian R Marshall; Anath C Lionel; Stephen Mack; Adrian Dubuc; Yuan Yao; Vijay Ramaswamy; Betty Luu; Adi Rolider; Florence M G Cavalli; Xin Wang; Marc Remke; Xiaochong Wu; Readman Y B Chiu; Andy Chu; Eric Chuah; Richard D Corbett; Gemma R Hoad; Shaun D Jackman; Yisu Li; Allan Lo; Karen L Mungall; Ka Ming Nip; Jenny Q Qian; Anthony G J Raymond; Nina T Thiessen; Richard J Varhol; Inanc Birol; Richard A Moore; Andrew J Mungall; Robert Holt; Daisuke Kawauchi; Martine F Roussel; Marcel Kool; David T W Jones; Hendrick Witt; Africa Fernandez-L; Anna M Kenney; Robert J Wechsler-Reya; Peter Dirks; Tzvi Aviv; Wieslawa A Grajkowska; Marta Perek-Polnik; Christine C Haberler; Olivier Delattre; Stéphanie S Reynaud; François F Doz; Sarah S Pernet-Fattet; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Wolfram Scheurlen; Charles G Eberhart; Michelle Fèvre-Montange; Anne Jouvet; Ian F Pollack; Xing Fan; Karin M Muraszko; G Yancey Gillespie; Concezio Di Rocco; Luca Massimi; Erna M C Michiels; Nanne K Kloosterhof; Pim J French; Johan M Kros; James M Olson; Richard G Ellenbogen; Karel Zitterbart; Leos Kren; Reid C Thompson; Michael K Cooper; Boleslaw Lach; Roger E McLendon; Darell D Bigner; Adam Fontebasso; Steffen Albrecht; Nada Jabado; Janet C Lindsey; Simon Bailey; Nalin Gupta; William A Weiss; László Bognár; Almos Klekner; Timothy E Van Meter; Toshihiro Kumabe; Teiji Tominaga; Samer K Elbabaa; Jeffrey R Leonard; Joshua B Rubin; Linda M Liau; Erwin G Van Meir; Maryam Fouladi; Hideo Nakamura; Giuseppe Cinalli; Miklós Garami; Peter Hauser; Ali G Saad; Achille Iolascon; Shin Jung; Carlos G Carlotti; Rajeev Vibhakar; Young Shin Ra; Shenandoah Robinson; Massimo Zollo; Claudia C Faria; Jennifer A Chan; Michael L Levy; Poul H B Sorensen; Matthew Meyerson; Scott L Pomeroy; Yoon-Jae Cho; Gary D Bader; Uri Tabori; Cynthia E Hawkins; Eric Bouffet; Stephen W Scherer; James T Rutka; David Malkin; Steven C Clifford; Steven J M Jones; Jan O Korbel; Stefan M Pfister; Marco A Marra; Michael D Taylor
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

7.  Dissecting the genomic complexity underlying medulloblastoma.

Authors:  David T W Jones; Natalie Jäger; Marcel Kool; Thomas Zichner; Barbara Hutter; Marc Sultan; Yoon-Jae Cho; Trevor J Pugh; Volker Hovestadt; Adrian M Stütz; Tobias Rausch; Hans-Jörg Warnatz; Marina Ryzhova; Sebastian Bender; Dominik Sturm; Sabrina Pleier; Huriye Cin; Elke Pfaff; Laura Sieber; Andrea Wittmann; Marc Remke; Hendrik Witt; Sonja Hutter; Theophilos Tzaridis; Joachim Weischenfeldt; Benjamin Raeder; Meryem Avci; Vyacheslav Amstislavskiy; Marc Zapatka; Ursula D Weber; Qi Wang; Bärbel Lasitschka; Cynthia C Bartholomae; Manfred Schmidt; Christof von Kalle; Volker Ast; Chris Lawerenz; Jürgen Eils; Rolf Kabbe; Vladimir Benes; Peter van Sluis; Jan Koster; Richard Volckmann; David Shih; Matthew J Betts; Robert B Russell; Simona Coco; Gian Paolo Tonini; Ulrich Schüller; Volkmar Hans; Norbert Graf; Yoo-Jin Kim; Camelia Monoranu; Wolfgang Roggendorf; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Andreas von Deimling; Olaf Witt; Eberhard Maass; Jochen Rössler; Martin Ebinger; Martin U Schuhmann; Michael C Frühwald; Martin Hasselblatt; Nada Jabado; Stefan Rutkowski; André O von Bueren; Dan Williamson; Steven C Clifford; Martin G McCabe; V Peter Collins; Stephan Wolf; Stefan Wiemann; Hans Lehrach; Benedikt Brors; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Paul A Northcott; Michael D Taylor; Matthew Meyerson; Scott L Pomeroy; Marie-Laure Yaspo; Jan O Korbel; Andrey Korshunov; Roland Eils; Stefan M Pfister; Peter Lichter
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

8.  The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children.

Authors:  Nicolas R Smoll; Katharine J Drummond
Journal:  J Clin Neurosci       Date:  2012-09-13       Impact factor: 1.961

9.  Long-term outcome of posterior fossa medulloblastoma in patients surviving more than 20 years following primary treatment in childhood.

Authors:  Radek Frič; Bernt Johan Due-Tønnessen; Tryggve Lundar; Arild Egge; Bård Kronen Krossnes; Paulina Due-Tønnessen; Einar Stensvold; Petter Brandal
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

10.  Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.

Authors:  Marcel Kool; Jan Koster; Jens Bunt; Nancy E Hasselt; Arjan Lakeman; Peter van Sluis; Dirk Troost; Netteke Schouten-van Meeteren; Huib N Caron; Jacqueline Cloos; Alan Mrsić; Bauke Ylstra; Wieslawa Grajkowska; Wolfgang Hartmann; Torsten Pietsch; David Ellison; Steven C Clifford; Rogier Versteeg
Journal:  PLoS One       Date:  2008-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.